Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation

Bibliography

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-5
   PubMed Web of Science ®Google Scholar
• Björck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013;44(11):3103-8
   PubMed Web of Science ®Google Scholar
• Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111(6):1167-76
   PubMed Web of Science ®Google Scholar
• Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110(2):213-22
   PubMed Web of Science ®Google Scholar
• Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32(2):392-8
   PubMed Web of Science ®Google Scholar
• Sanna T, Diener HC, Passman RS, et al. CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370(26):2478-86
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Europace 2012;14(10):1385-413
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014. [ Epub ahead of print]
   Google Scholar
• Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011;106(4):739-49
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip G. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study. Circulation 2012;125(19):2298-307
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263-72
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. Best Pract Res Clin Haematol 2013;26(2):115-29
   PubMed Web of Science ®Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104(1):49-60
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15(5):625-51
   PubMed Web of Science ®Google Scholar
• Pradaxa: European public assessment report – product information. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf [Accessed 5 September 2014]
   Google Scholar
• Pradaxa: Prescribing information and medication guide. Revised 8/2014. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf [5 Accessed September 2014]
   Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110(6):1087-107
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109(4):569-79
   PubMed Web of Science ®Google Scholar
• Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011;127(Suppl 2):S5-12
   PubMed Web of Science ®Google Scholar
• Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost 2014;111(4):625-33
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Steahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate — a new oral direct thrombin inhibitor - in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303
   PubMed Web of Science ®Google Scholar
• Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47(1):47-59
   PubMed Web of Science ®Google Scholar
• Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52:69-82
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123(13):1436-50
   PubMed Web of Science ®Google Scholar
• Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013;29(7 Suppl):S24-33
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363(19):1875-6
   PubMed Web of Science ®Google Scholar
• Oldgren J, Alings M, Darius H, et al. RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011;155(10):660-7
   PubMed Web of Science ®Google Scholar
• Diener HC, Connolly SJ, Ezekowitz MD, et al. RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9(12):1157-63
   PubMed Web of Science ®Google Scholar
• Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013;109(2):328-36
   PubMed Web of Science ®Google Scholar
• Lip GY, Clemens A, Noack H, et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014;111(5):933-42
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013;128(3):237-43
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available from: http://www.fda.gov/drugs/drugsafety/ucm282724.htm [Accessed 23 July 2014]
   Google Scholar
• Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368(14):1272-4
   PubMed Web of Science ®Google Scholar
• FDA drug safety communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm [Accessed 23 July 2014]
   Google Scholar
• FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm [Accessed 23 July 2014]
   Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61(22):2264-73
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ’real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107(3):584-9
   PubMed Web of Science ®Google Scholar
• Paré G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404-12
   PubMed Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321-8
   PubMed Web of Science ®Google Scholar
• Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670
   PubMed Web of Science ®Google Scholar
• Charlton B, Redberg R. The trouble with dabigatran. BMJ 2014;349:g4681
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014;349:g4517
   PubMed Web of Science ®Google Scholar
• Pradaxa: CHMP assessment report. 2011. Available from: http://www.ema.europa.eu [Accessed 5 September 2014]
   Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123(2):131-6
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed. British Medical Journal publishes biased article regarding PRADAXA. Press Release 2014. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/07-23-14-benefits-safety-pradaxa-dabigatran-etexilate-mesylate-repeatedly-confirmed.html [Accessed 28 August 2014]
   Google Scholar
• Yadlapati A, Groh C, Passman R. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter. Am J Cardiol 2014;113(8):1362-3
   PubMed Web of Science ®Google Scholar
• Klein AL, Grimm RA, Murray RD, et al. Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20
   PubMed Web of Science ®Google Scholar
• Klein AL, Jasper SE, Katz WE, et al. ACUTE II Steering and Publications Committe for the ACUTE II Investigators. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 2006;27(23):2858-65
   PubMed Web of Science ®Google Scholar
• Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med 2001;110:694-702
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Baghaei F, Blixter IF, et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105(2):371-8
   PubMed Web of Science ®Google Scholar
• Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107(5):985-97
   PubMed Web of Science ®Google Scholar
• Hapgood G, Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013;110(2):308-15
   PubMed Web of Science ®Google Scholar
• Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-502
   PubMed Web of Science ®Google Scholar
• Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14(4):528-606
   PubMed Web of Science ®Google Scholar
• Lee DS, Dorian P, Downar E, et al. Thrombogenicity of radiofrequency ablation procedures: what factors influence thrombin generation? Europace 2001;3(3):195-200
   PubMed Web of Science ®Google Scholar
• Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302-11
   PubMed Web of Science ®Google Scholar
• Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129(25):2638-44
   PubMed Web of Science ®Google Scholar
• Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59(13):1168-74
   PubMed Web of Science ®Google Scholar
• Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013;15(11):1587-93
   PubMed Web of Science ®Google Scholar
• Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 2014;40(1):33-8
   PubMed Web of Science ®Google Scholar
• Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013;6(3):460-6
   PubMed Web of Science ®Google Scholar
• Haines DE, Mead-Salley M, Salazar M, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol 2013;37(3):233-9
   PubMed Web of Science ®Google Scholar
• Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013;36(2):172-9
   PubMed Web of Science ®Google Scholar
• Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10(4):483-9
   PubMed Web of Science ®Google Scholar
• Bin Abdulhak AA, Khan AR, Tleyjeh IM, et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15(10):1412-20
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15(10):1407-11
   PubMed Web of Science ®Google Scholar
• Providência R, Albenque JP, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014;100(4):324-35
   PubMed Web of Science ®Google Scholar
• Sardar P, Nairooz R, Chatterjee S, et al. Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 2014;113(7):1173-7
   PubMed Web of Science ®Google Scholar
• Shurrab M, Morillo CA, Schulman S, et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Can J Cardiol 2013;29(10):1203-10
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Hasselblad V, Atwater BD, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. J Interv Card Electrophysiol 2013;37(3):213-21
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Initiates RE-CIRCUIT™ Trial, Evaluating Pradaxa® (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation). Press Release 2014. Available from: http://www.us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/06-20-14-boehringer-ingelheim-re-circuit-trial-pradaxa-dabigatran-etexilate-mesylate-nvaf-patients-undergoing-ablation.html [Accessed 23 July 2014]
   Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, et al. European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34
   PubMed Web of Science ®Google Scholar
• Task Force Members. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;10.1093/eurheartj/ehu298. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010;104(4):657-63
   PubMed Web of Science ®Google Scholar
• Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127(5):634-40
   PubMed Web of Science ®Google Scholar
• Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123(9):785-9
   PubMed Web of Science ®Google Scholar
• Sipahi I, Celik S, Akyol A. Letter to the editor: efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation by Larsen et al. J Am Coll Cardiol 2013;62(10):945-6
   PubMedGoogle Scholar
• Douxfils J, Buckinx F, Mullier F, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3(3):e000515
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in ’real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med 2014;127(4):329-336.e4
   PubMed Web of Science ®Google Scholar
• Dale B, Eikelboom JW, Weitz JI, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 2013;35:295-301
   PubMed Web of Science ®Google Scholar
• Samama MM, Le Flem L, Guinet C, et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007;5(12):2554-6
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007;5(4):886-8
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Planning to Initiate Two New Global Clinical Trials of Pradaxa® (dabigatran etexilate mesylate). Press Release 2013. Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/11-19-2013-boehringer-ingelheim-global-clinical-trials-pradaxa-dabigatran-etexilate-mesylate.html [Accessed 23 July 2014]
   Google Scholar
• Banerjee A, Fauchier L, Vourc’h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014;145(6):1370-82
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Guo Y, Lane DA, et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013;34(46):3572-9
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Manzano-Fernandez S, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109(5):956-60
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367(7):625-35
   PubMed Web of Science ®Google Scholar
• Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9(11):2168-75
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Pradaxa study in non-valvular atrial fibrillation patients with severely impaired renal function. 2013. NLM Identifier: NCT01896297 Available from: http://www.clinicaltrials.gov/show/NCT01896297 [Accessed 23 July 2014]
   Google Scholar
• Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012;72(13):1739-53
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129(9):961-70
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. ESC Congress 2014 Hot Line Session: Favourable effect of Pradaxa® on kidney function over time compared to warfarin. Press release archive: SPAF 2014. Available from: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/02_september_2014_dabigatranetexilate.html [Accessed 5 September 2014]
   Google Scholar
• Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013;8(9):1533-9
   PubMed Web of Science ®Google Scholar
• Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis 2013;61(3):487-9
   PubMed Web of Science ®Google Scholar
• Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109(4):596-605
   PubMed Web of Science ®Google Scholar
• Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008;32(9):1431-7
   PubMed Web of Science ®Google Scholar
• Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292(20):2471-7
   PubMed Web of Science ®Google Scholar
• Huxley RR, Misialek JR, Agarwal SK, et al. Physical activity, obesity, weight change, and risk of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol 2014;7(4):620-5
   PubMed Web of Science ®Google Scholar
• Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278(5):F817-22
   PubMed Web of Science ®Google Scholar
• Han PY, Duffull SB, Kirkpatrick CMJ, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007;82(5):505-8
   PubMed Web of Science ®Google Scholar
• Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011;155(2):137-49
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Feuring M, et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res 2012;130(5):818-20
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35(28):1888-96
   PubMed Web of Science ®Google Scholar
• Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis. 9th edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-50S
   PubMed Web of Science ®Google Scholar
• Nitzki-George D, Wozniak I, Caprini JA. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother 2013;47(6):841-55
   PubMed Web of Science ®Google Scholar
• Pernod G, Albaladejo P, Godier A, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013;106(6-7):382-93
   PubMed Web of Science ®Google Scholar
• Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014;111(2):189-98
   PubMed Web of Science ®Google Scholar
• Miesbach W, Seifried E. New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012;108(4):625-32
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Reversal of dabigatran anticoagulant effect with idarucizumab. 2014. NLM Identifier: NCT02104947 Available from: http://clinicaltrials.gov/show/NCT02104947 [ Accessed 23 July 2014]
   Google Scholar
• Healey JS, Eikelboom J, Douketis J, et al. RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126(3):343-8
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369(13):1206-14
   PubMed Web of Science ®Google Scholar
• Thorne K, Jayathissa S, Dee S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J 2014;44(3):261-5
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11(7):1295-9
   PubMed Web of Science ®Google Scholar
• Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014;167(6):810-17
   PubMed Web of Science ®Google Scholar
• Tsai K, Erickson SC, Yang J, et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013;19(9):e325-32
   PubMed Web of Science ®Google Scholar
• Barker RV, Lip GY, Lane DA. Best practice for atrial fibrillation patient education. Curr Pharm Des 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 2013;6:CD008600
   PubMedGoogle Scholar
• Clarkesmith DE, Pattison HM, Lip GY, et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 2013;8(9):e74037
   PubMed Web of Science ®Google Scholar
• Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167(3):329-34
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163(1):13-19.e1
   PubMed Web of Science ®Google Scholar
• Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014;111(3):465-73
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106(5):968-77
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144(5):1555-63
   PubMed Web of Science ®Google Scholar
• Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014;9(4):443-7
   PubMed Web of Science ®Google Scholar
• Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAME-TT2R2 score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest 2014;10.1378/chest.13-2976. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007;21(1):1-11
   PubMed Web of Science ®Google Scholar